Trials / Recruiting
RecruitingNCT07166302
Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 70 (estimated)
- Sponsor
- Masaryk University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Approximately 30 minutes after needle EMG, patients who are taking direct oral anticoagulants (DOACs) will undergo an ultrasound examination to evaluate for the presence of possible intramuscular hematomas at the muscles where the EMG needle was inserted. These hematomas are considered a potential adverse effect of needle EMG. The aim of the study is to determine whether needle EMG can be considered a safe procedure in this group of patients, without posing a risk of intramuscular hematoma formation.
Conditions
- Direct Acting Anticoagulant Adverse Reaction
- Needle Injury
- EMG
- Peripheral Neuropathies
- Mononeuropathies
- Polyneuropathies
- Neuromuscular Diseases (NMD)
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2026-06-30
- Completion
- 2026-12-31
- First posted
- 2025-09-10
- Last updated
- 2025-09-10
Locations
2 sites across 1 country: Czechia
Source: ClinicalTrials.gov record NCT07166302. Inclusion in this directory is not an endorsement.